This application is based upon and claims priority to Chinese Patent Application No. 202211315197.9, filed on Oct. 26, 2022, the entire contents of which are incorporated herein by reference.
The present invention relates to the fields of medicines and biotechnology, and in particular to a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme and a preparation method therefor and an application thereof.
Malignant tumors are a class of refractory diseases that seriously threaten human life and health. At present, the conventional methods for clinically treating cancers, such as radiotherapy, chemotherapy, and surgery, still face problems such as large side effects, high recurrence rate, and limited therapeutic effect. This is due to the rapid proliferation of tumor cells and severe shortage of blood supply, TME has typical hypoxic characteristics, and the hypoxic area of the tumor is resistant to radiotherapy and chemotherapy due to lack of oxygen. In addition to the characteristics of severe hypoxia, the tumor microenvironment also has the problem of GSH overexpression. Overexpressed GSH will consume highly biotoxic reactive oxygen species (ROS), thereby reducing the efficacy of various tumor treatment modalities. In recent years, sonodynamic therapy, which stimulates sonosensitizers to generate ROS through the action of ultrasound, has been considered as an effective method to improve the status quo of cancer treatment. However, previously developed organic sonosensitizers can only rely on oxygen to generate singlet oxygen, and this single ROS generation mechanism is easily limited by the tumor hypoxic microenvironment. Compared with organic sonosensitizers, inorganic semiconductor nanomaterials such as titanium dioxide (TiO2) have the advantages of chemical inertness to biological tissues, low cost, and easy fabrication, and therefore have been widely used in sonodynamic therapy (SDT) in recent years. However, the wide band gap structure of TiO2 (3.2 eV) and the rapid recombination of electron-hole pairs (50±30 ns) decrease the quantum yield of ROS, resulting in poor SDT therapeutic effect. Therefore, designing and synthesizing a novel high-efficiency sonosensitizer, which has the capabilities of enhancing sonodynamic performance and regulating TME, is the focus and the difficulty of the current SDT research.
In view of this, the present invention provides a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme and a preparation method therefor and an application thereof.
Aiming at the deficiencies in the prior art, the present invention is intended to provide a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme, which aims to solve the problems of low ROS quantum yield, easy consumption of ROS by endogenous GSH, and the like of the existing nanosonosensitizer, and enhances the sonodynamic therapeutic effect of cancer by effectively regulating and controlling TME through catalyzing and generating endogenous O2.
In order to solve the technical problems described above, the present invention provides the following technical solutions.
A cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme comprises: a surface oxygen vacancy doped TiO2-x nanosheet and a variable-valence metal-containing Co3O4 nanozyme, wherein the Co3O4 nanozyme is loaded on the surface of the TiO2-x nanosheet to construct and obtain the Co3O4@TiO2-x heterojunction nanozyme.
A preparation method for the cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme comprises the following steps:
Further, a preparation method for the Co3O4 nanozyme comprises the following steps:
(1) 20-60 mg of Co(CH3COO)2·4H2O is firstly weighed and dissolved in 10-25 mL of ethanol, and is put into a reaction kettle for reaction after complete dissolution, wherein a temperature in the reaction kettle is controlled to be 120-180° C. and a reaction time is controlled to be 3-5 h, to obtain a Co3O4 nanozyme reaction mixture;
(2) after the reaction is completed, the Co3O4 nanozyme reaction mixture is cooled to room temperature, and the Co3O4 nanozyme reaction mixture is taken out for centrifugation, and the reaction mixture is washed 2-5 times by using deionized water and ethanol, and is finally dried under vacuum at a temperature of 40-80° C. to obtain the Co3O4 nanozyme powders.
Further, a preparation method for the surface oxygen vacancy doped TiO2-x nanosheet comprises the following steps:
An application of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme generating singlet oxygen in the sonodynamic performance, wherein the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is enabled to generate a large amount of singlet oxygen under low-intensity ultrasound, and a singlet oxygen generation efficiency of the Co3O4@TiO2-x heterojunction nanozyme under ultrasonic irradiation is detected by using 1,3-diphenylisobenzofuran as a singlet oxygen probe and detecting a change of absorption peak intensities at 412 nm under different ultrasonic times by using an ultraviolet spectrophotometer.
An application of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme generating hydroxyl radicals in the chemical kinetic performance, wherein the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is enabled to generate a large amount of hydroxyl radicals under low-intensity ultrasound, and a hydroxyl radical generation efficiency of the Co3O4@TiO2-x heterojunction nanozyme under ultrasonic irradiation is detected by using 3,3,5,5-tetramethylbenzidine as a probe and detecting a change of absorption peak intensities at 654 nm under different ultrasonic times by using an ultraviolet spectrophotometer.
An application of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme in consuming glutathione to improve the tumor microenvironment, wherein the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is used to evaluate the Co3O4@TiO2-x heterojunction nanozyme in consuming glutathione (GSH) to improve the tumor microenvironment by using 5,5′-dithiobis (2-nitrobenzoic acid) as a glutathione probe.
An application of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme in promoting generation of endogenous O2 to improve the tumor microenvironment, wherein the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is used to detect oxygen generation amount of aqueous material solutions at different pH values after H2O2 at different concentrations is added by using a dissolved oxygen detector to improve the tumor microenvironment.
An application of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme in in vivo sonodynamic reduction of tumor cells.
Use of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme in preparing a medicine for treating tumors, wherein the medicine for treating tumors comprises a solvent, and 0.1-6 mg of a Co3O4@TiO2-x heterojunction nanozyme is contained in every 1 mL of a medicine liquid, wherein the solvent and the Co3O4@TiO2-x heterojunction nanozyme form a Co3O4@TiO2-x tumor medicine liquid, and the Co3O4@TiO2-x heterojunction nanozyme tumor medicine liquid is administrated to a receptor through intravenous injection.
Further, the solvent is normal saline.
Further, the receptor is an animal containing tumor cells.
With the adoption of the above technical solution, the present invention has the following beneficial effects:
The present invention provides a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme and a preparation method therefor and an application thereof. The Co3O4@TiO2-x heterojunction nanozyme is used as a nanozyme to catalyze and generate endogenous O2 and consume GSH, so as to improve the tumor microenvironment (TME), and achieve the effect of eradicating tumors by cooperating with sonodynamic therapy and catalytic therapy. The Co3O4@TiO2-x heterojunction nanozyme prepared by the present invention not only has an enhanced sonodynamic performance and tumor catalytic treatment performance, but also has tumor microenvironment regulation and control capabilities of relieving tumor hypoxia and consuming GSH, thus realizing the amplification of ROS quantum yield. The nanozyme has a high biocompatibility, no obvious long-term toxicity, a low cost, a high activity, and a good thermal stability, and therefore is suitable for large-scale production.
The present invention is further illustrated below with reference to the accompanying drawing.
In order to make the objectives, technical solutions and advantages of the present invention more apparent and clear, the present invention is further described in detail below with reference to the accompanying drawings and examples. It should be understood that the specific examples described herein are merely illustrative of the present invention and do not limit the scope of the present invention. Moreover, in the following description, descriptions of well-known structures and techniques are omitted to avoid unnecessarily obscuring the concept of the present invention.
Referring to
A preparation method for the cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme comprises the following steps:
Further, a preparation method for the Co3O4 nanozyme comprises the following steps:
Further, a preparation method for the surface oxygen vacancy doped TiO2-x nanosheet comprises the following steps:
Use of a cobaltosic oxide-loaded titanium dioxide heterojunction nanozyme in preparing a medicine for treating tumors, wherein the medicine for treating tumors comprises a solvent, and 0.1-6 mg of a Co3O4@TiO2-x heterojunction nanozyme is contained in every 1 mL of a medicine liquid, wherein the solvent and the Co3O4@TiO2-x heterojunction nanozyme form a Co3O4@TiO2-x tumor medicine liquid, and the Co3O4@TiO2-x heterojunction nanozyme tumor medicine liquid is administrated to a receptor through intravenous injection. The solvent is normal saline, and the receptor is an animal containing tumor cells.
An application of a Co3O4@TiO2-x heterojunction nanozyme generating singlet oxygen in the sonodynamic performance is characterized in that the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is enabled to generate a large amount of singlet oxygen under low-intensity ultrasound, the chemical formula for singlet oxygen is 1O2, and a singlet oxygen generation efficiency of the Co3O4@TiO2-x heterojunction nanozyme under ultrasonic irradiation is detected by using 1,3-diphenylisobenzofuran as a singlet oxygen probe and detecting a change of absorption peak intensities at 412 nm under different ultrasonic times by using an ultraviolet spectrophotometer, so as to evaluate the sonodynamic performance of the heterojunction nanozyme. Specifically, referring to
An application of a Co3O4@TiO2-x heterojunction nanozyme generating hydroxyl radicals in the chemical kinetic performance is characterized in that the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is enabled to generate a large amount of hydroxyl radicals under low-intensity ultrasound, the chemical formula of hydroxyl radical is OH, and a hydroxyl radical generation efficiency of the Co3O4@TiO2-x heterojunction nanozyme under ultrasonic irradiation is detected by using 3,3,5,5-tetramethylbenzidine as a probe and detecting a change of absorption peak intensities at 654 nm under different ultrasonic times by using an ultraviolet spectrophotometer, so as to evaluate the chemical kinetic performance of the heterojunction nanozyme. Specifically, referring to
An application of a Co3O4@TiO2-x heterojunction nanozyme in consuming glutathione (GSH) to improve the tumor microenvironment is characterized in that the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is used to evaluate the Co3O4@TiO2-x heterojunction nanozyme in consuming GSH to improve the tumor microenvironment by using 5,5′-dithiobis (2-nitrobenzoic acid) as a glutathione probe. It can be seen from
An application of a Co3O4@TiO2-x heterojunction nanozyme in promoting generation of endogenous O2 to improve the tumor microenvironment is characterized in that the Co3O4@TiO2-x heterojunction nanozyme prepared by the above method is used to detect oxygen generation amount of aqueous material solutions at different pH values after H2O2 at different concentrations is added by using a dissolved oxygen detector to improve the tumor microenvironment. It can be seen from
An application of a Co3O4@TiO2-x heterojunction nanozyme in in vivo sonodynamic reduction of tumor cells. Female nude mice aged 3-5 weeks were subcutaneously implanted with 100 μL (5 million) of human osteosarcoma cells (143B) at the armpit, and when the tumor volume reached 100 mm3, the nude mice were divided into 5 groups (5 per group).
Group (1), blank control group: specifically, 5 nude mice of group (1) were injected with 500 mL of normal saline every day without US irradiation.
Group (2), with US irradiation alone (50 kHz, 2.0 Wcm−2, 5 min): specifically, 5 nude mice of group (2) were injected with 500 mL of normal saline every day and subjected to US irradiation (50 kHz, 2.0 Wcm−2) for 5 min.
Group (3), with Co3O4@TiO2-x heterojunction nanozyme: specifically, 5 nude mice in the group (3) were injected with 500 mL of Co3O4@TiO2-x heterojunction nanozyme normal saline solution every day, and each 1 mL of Co3O4@TiO2-x heterojunction nanozyme normal saline solution contained 3 mg of Co3O4@TiO2-x heterojunction nanozyme, and US irradiation was not performed.
Group (4), irradiated with Co3O4+US irradiation (50 kHz, 2.0 Wcm−2, 5 min): specifically, 5 nude mice of group (4) were injected with 500 mL of Co3O4 normal saline solution every day, each 1 mL of Co3O4 normal saline solution contained 3 mg of Co3O4, and US irradiation (50 kHz, 2.0 Wcm−2) was performed for 5 min.
Group (5), with Co3O4@TiO2-x+US irradiation (50 kHz, 2.0 Wcm−2, 5 min): specifically, 500 mL of Co3O4@TiO2-x heterojunction nanozyme normal saline solution was injected into 5 nude mice in the group (5) every day, and each 1 mL of Co3O4@TiO2-x heterojunction nanozyme normal saline solution contained 3 mg of Co3O4@TiO2-x heterojunction nanozyme, and US irradiation (50 kHz, 2.0 Wcm−2) was performed for 5 min.
Body weights of 25 nude mice were recorded every day and tumor volume size was measured every other day to evaluate the in vivo sonodynamic therapeutic efficacy of Co3O4@TiO2-x heterojunction nanozyme.
The experimental results are as follows with reference to
The nude mice of group (1) had a tumor volume that increased from 100 mm 3 to 1855 mm3 after 14 days.
The nude mice of group (2) had a tumor volume that increased from 100 mm 3 to 1840 mm3 after 14 days.
The results of the group (3) are shown in
The results of the group (4) are shown in
The results of the group (5) are shown in
According to the above experiments, referring to
According to the above experiments, referring to
The present invention firstly achieves the purpose of reducing the band gap of TiO2 by preparing a surface oxygen vacancy doped TiO2-x nanosheet, so that electrons of TiO2 are easier to be excited under the action of US; and then loads Co3O4 nanozyme containing valence-variable metal (Co2+/3+) on the surface of the TiO2-x nanosheet to construct Co3O4@TiO2-x heterojunction nanozyme, so that the carrier transmission rate is greatly accelerated, the recombination of electron-hole pairs is inhibited, and the quantum yield of ROS is further improved. The Co3O4@TiO2-x heterojunction nanozyme not only has peroxidase activity, which can catalyze hydrogen peroxide to generate a large amount of OH, but also has excellent catalase activity, which can catalyze hydrogen peroxide to generate a large amount of oxygen, thereby improving the performance of sonodynamic therapy (SDT). The high-valence metal ions (Co3+) in the Co3O4@TiO2-x heterojunction nanozyme can also consume GSH, and achieve the purpose of improving TME, thereby enhancing the curative effect of tumor treatment.
The heterojunction nanozyme prepared in this example is subjected to related experiments such as characterization, detection of sonodynamic performance, detection of GSH consumption ability, detection of hydrogen peroxide catalytic ability, detection of intracellular GSH content, determination of cytotoxicity by an MTT method, treatment of tumors in vivo by an intravenous injection mode, and the like through instrument, and specific results are summarized as follows:
It can be seen from
It can be seen from
It can be seen from
It can be seen from
It can be seen from
It can be seen from
The above are only specific examples of the present invention, and the technical features of the present invention are not limited thereto. Any simple changes, equivalent replacements or modifications based on the present invention to solve basically the same technical problems and achieve basically the same technical effects are covered by the protection scope of the present invention.
Number | Date | Country | Kind |
---|---|---|---|
202211315197.9 | Oct 2022 | CN | national |